Example: Heart Attack

Clinical Trials on Castleman Disease

Total 29 results

    • NCT04585893
      Not yet recruiting
      Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
      Conditions: Multicentric Castleman Disease
    • NCT03933904
      Recruiting
      Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
      Conditions: Castleman Disease; Castleman's Disease, Multicentric
    • NCT03982771
      Recruiting
      BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)
      Conditions: Idiopathic Multicentric Castleman's Disease
    • NCT01400503
      Completed
      A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
      Conditions: Multicentric Castleman's Disease
    • NCT01183598
      Completed
      A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment
      Conditions: Castleman's Disease
    • NCT01024036
      Completed
      A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
      Conditions: Multicentric Castleman's Disease
    • NCT03043105
      Active, not recruiting
      TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial
      Conditions: Multicentric Castleman Disease
    • NCT01441063
      Completed
      Tocilizumab for KSHV-Associated Multicentric Castleman Disease
      Conditions: Castleman Disease; Multicentric Castleman Disease; Giant Lymph Node Hyperplasia
    • NCT00361933
      Withdrawn
      Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease
      Conditions: Giant Lymph Node Hyperplasia
    • NCT00127569
      Terminated
      Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
      Conditions: HIV Infections; Giant Lymph Node Hyperplasia
    • NCT02871050
      Withdrawn
      Castleman Disease Collaborative Network Biobank
      Conditions: Castleman Disease; Castleman's Disease; Giant Lymph Node Hyperplasia; Angiofollicular Lymph Hyperplasia; Angiofollicular Lymph Node Hyperplasia; Angiofollicular Lymphoid Hyperplasia; GLNH; Hyperplasia; Giant Lymph Node
    • NCT02853968
      Completed
      Unlock the Cell: Castleman's Disease Flow Cytometry Study
      Conditions: Castleman Disease; Angiofollicular Lymphoid Hyperplasia; GLNH; Hyperplasia; Castleman's Disease; Angiofollicular Lymph Hyperplasia; Giant Lymph Node Hyperplasia
    • NCT02817997
      Recruiting
      International Registry for Patients With Castleman Disease
      Conditions: Castleman Disease; Castleman's Disease; Giant Lymph Node Hyperplasia; Angiofollicular Lymph Hyperplasia; Angiofollicular Lymph Node Hyperplasia; Angiofollicular Lymphoid Hyperplasia; GLNH; Hyperplasia, Giant Lymph Node; Lymph Node Hyperplasia, Giant
    • NCT03300830
      Recruiting
      Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
      Conditions: Human Immunodeficiency Virus; Castleman's Disease; Kaposi's Sarcoma; Viral-Associated Cancer
    • NCT00412321
      Completed
      A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
      Conditions: Lymphoma, Non-Hodgkin; Multiple Myeloma; Giant Lymph Node Hyperplasia
    • NCT02228512
      Withdrawn
      Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
      Conditions: Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease; Primary Effusion Lymphoma
    • NCT00002652
      Completed
      Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease
      Conditions: Multiple Myeloma and Plasma Cell Neoplasm
    • NCT03864419
      Recruiting
      Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
      Conditions: Burkitt Lymphoma; KSHV-associated Multicentric Castleman Disease; Diffuse Large B-Cell Lymphoma
    • NCT00891280
      Unknown status
      Dose-escalation Study of Oral CX-4945
      Conditions: Advanced Solid Tumors; Breast Cancer; Inflammatory Breast Cancer; Castleman's Disease; Multiple Myeloma
    • NCT00092222
      Recruiting
      Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
      Conditions: Lymphoproliferative Disorder; HHV-8; Malignancy; HIV
    • NCT00006518
      Recruiting
      Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
      Conditions: HIV; Kaposi's Sarcoma; Lymphomas; Multicentric Castleman's Disease; Primary Effusion Lymphoma
    • NCT02080416
      Terminated
      Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
      Conditions: Non-Hodgkin Lymphoma; Hodgkin Lymphoma; Kaposi Sarcoma; Gastric Cancer; Nasopharyngeal Cancer; EBV; Castleman Disease
    • NCT03169595
      Completed
      Epithelioid Hemangioma of Bone And Soft Tissue
      Conditions: Epithelioid Hemangioma of Bone; Epithelioid Hemangioma
    • NCT03717844
      Recruiting
      Registry for Adults With Plasma Cell Disorders (PCD's)
      Conditions: Multiple Myeloma; Amyloidosis; Cryoglobulinemia; Castleman's Disease; Light Chain Deposition Disease; Heavy Chain Deposition Disease; Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes; Smoldering Multiple Myeloma; Plasma Cell Leukemia
    • NCT01552434
      Recruiting
      Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
      Conditions: Advanced Malignant Neoplasm; Castleman Disease; Digestive System Carcinoma; Erdheim-Chester Disease; Lip and Oral Cavity Carcinoma; Lymphangioleiomyomatosis; Malignant Endocrine Neoplasm; Malignant Female Reproductive System Neoplasm; Malignant Male Reproductive System Neoplasm; Malignant Neoplasm; Malignant Respiratory Tract Neoplasm; Malignant Thoracic Neoplasm; Malignant Urinary System Neoplasm; Mesothelial Neoplasm; Metastatic Malignant Neoplasm; Metastatic Urothelial Carcinoma; Neurofibromatosis Type 2; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Digestive System Carcinoma; Recurrent Female Reproductive System Carcinoma; Recurrent Male Reproductive System Carcinoma; Recurrent Malignant Neoplasm; Recurrent Pharyngeal Carcinoma; Recurrent Thyroid Gland Carcinoma; Refractory Malignant Neoplasm; Soft Tissue Neoplasm; Stage III Breast Cancer AJCC v7; Stage III Pharyngeal Cancer; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Stage IV Pharyngeal Cancer; Stage IVA Pharyngeal Cancer; Stage IVB Pharyngeal Cancer; Stage IVC Pharyngeal Cancer; Thyroid Gland Neoplasm
      Medical Conditions
      Sponsors and Collaborators
      Drug Interventions
      Conditions
      Rare Diseases
      Drug Interventions
      Dietary Supplements
      Sponsor/Collaborators
      Locations